Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine on the Pharmacokinetics of Atazanavir in HIV-Infected Subjects Receiving Atazanavir With Ritonavir and Tenofovir

The purpose of this study is to assess the effects of famotidine, given twice daily, on atazanavir administered with ritonavir and tenofovir in HIV-infected participants.

Study Overview

• Status: Completed
• Conditions: HIV
• Intervention / Treatment: Drug: Atazanavir; Drug: Atazanavir; Drug: Ritonavir; Drug: Ritonavir; Drug: Tenofovir (TDF); Drug: Tenofovir (TDF); Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Drug: Famotidine (FAM); Drug: Famotidine (FAM)

Detailed Description

This protocol was designed to compare the pharmacokinetic parameters of atazanavir administered as atazanavir/ritonavir, 400/100 mg once daily (QD), plus famotidine, 20 mg and 40 mg twice daily, with the parameters found at the usual clinical dose of atazanavir/ritonavir, 300/100 mg QD, without famotidine in HIV-infected participants receiving tenofovir disoproxil fumarate and at least 1 other nucleoside reverse transcriptase inhibitor.

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Phase 4

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 14050
    • Local Institution
• United Kingdom
  • Greater London
    • London, Greater London, United Kingdom, SW10 9NH
      • Local Institution

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key inclusion criteria:

• Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m^2
• HIV-infected participants receiving a treatment regimen containing only atazanavir/ritonavir, 300/100 mg once daily (QD) + tenofovir, 300 mg QD + at least 1 other nucleotide reverse transcriptase inhibitor continuously for at least 3 months prior to study day 1
• Plasma HIV RNA levels of <50 copies/mL and a CD4 count >200 cells/mm^3.
• No history of virologic failure on a protease inhibitor (PI), documented phenotypic PI resistance, or primary PI mutations, according to International AIDS Society recommendations
• No documented phenotypic resistance to atazanavir or primary genotypic mutations causing resistance to atazanavir
• Women of childbearing potential who were not nursing or pregnant and were using an acceptable method of contraception for at least 4 weeks before dosing, during the study, and for 8 weeks from the last dose of study drug.
• Women with a negative pregnancy test result within 24 hours prior to dosing with study medication
• Women not breastfeeding
• Men willing or able to agree to practice barrier contraception for the duration of the study and at least 3 months after dosing.

Key exclusion criteria:

• Any history of CD4 cell count <50 cells/mm^3
• Previously documented phenotypic or genotypic resistance to any of the currently prescribed NRTIs
• Any significant acute illness within 6 months of study day 1 or chronic medical illness unless stable or controlled by a nonprohibited medication
• Any major surgery within 4 weeks of study day 1
• Any gastrointestinal surgery that could impact upon the absorption of any study drug
• Inability to be venipunctured and/or tolerate venous access
• History of Gilbert's syndrome, hemophilia, chronic pancreatitis, hypochlorhydria, achlorhydria, clinically relevant gastroesophageal reflux disease, hiatal hernia, or peptic/gastric ulcer disease
• Intractable diarrhea (≥ 6 loose stools/day for at least 7 consecutive days) within 30 days prior to study day 1
• Recent (within 6 months prior to study day 1) drug or alcohol abuse
• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ECG)
• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations, which would not be expected for the extent of HIV disease
• Any of the following on 12-lead ECG prior to dosing on study day 1, confirmed by repeat: PR ≥ 210 msec; QRS ≥ 120 msec; QT ≥ 500 msec; QTcF ≥ 450 msec
• Second- or third-degree A-V block or clinically relevant ECG abnormalities
• Positive urine screen for drugs of abuse at screening or prior to dosing without a valid prescription. Positive urine drug screen for cannabinoids with or without a prescription is not exclusionary
• Creatinine clearance, as estimated by method of Cockcroft and Gault, less than 60 mL/min
• Liver enzyme levels > 3* the upper limit of normal (ULN) prior to dosing on study day 1
• Total bilirubin level >10*ULN prior to study day 1
• Positive blood screen for hepatitis B surface antigen or hepatitis C antibody.

Study Plan

How is the study designed?

Design Details

• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI; The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.	Drug: Atazanavir; Capsule, oral, 300 mg, once daily, 10 days; Other Names: Reyataz; BMS-232632; Drug: Atazanavir; Capsule, oral, 400 mg, once daily, 7 days; Other Names: Reyataz; BMS-232632; Drug: Ritonavir; Capsule, oral, 100 mg, once daily, 10 days; Drug: Ritonavir; Capsule, oral, 100 mg, once daily, 7 days; Drug: Tenofovir (TDF); Capsule, oral, 300 mg, once daily, 10 days; Drug: Tenofovir (TDF); Capsule, oral, 300 mg, once daily, 7 days; Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Oral, 10 days; Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Oral, 7 days
Other: Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20); FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.	Drug: Atazanavir; Capsule, oral, 300 mg, once daily, 10 days; Other Names: Reyataz; BMS-232632; Drug: Atazanavir; Capsule, oral, 400 mg, once daily, 7 days; Other Names: Reyataz; BMS-232632; Drug: Ritonavir; Capsule, oral, 100 mg, once daily, 10 days; Drug: Ritonavir; Capsule, oral, 100 mg, once daily, 7 days; Drug: Tenofovir (TDF); Capsule, oral, 300 mg, once daily, 10 days; Drug: Tenofovir (TDF); Capsule, oral, 300 mg, once daily, 7 days; Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Oral, 10 days; Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Oral, 7 days; Drug: Famotidine (FAM); Tablet, oral, 20 mg, twice daily, 7 days; Drug: Famotidine (FAM); Tablet, oral, 40 mg, twice daily, 7 days
Other: Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40); FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.	Drug: Atazanavir; Capsule, oral, 300 mg, once daily, 10 days; Other Names: Reyataz; BMS-232632; Drug: Atazanavir; Capsule, oral, 400 mg, once daily, 7 days; Other Names: Reyataz; BMS-232632; Drug: Ritonavir; Capsule, oral, 100 mg, once daily, 10 days; Drug: Ritonavir; Capsule, oral, 100 mg, once daily, 7 days; Drug: Tenofovir (TDF); Capsule, oral, 300 mg, once daily, 10 days; Drug: Tenofovir (TDF); Capsule, oral, 300 mg, once daily, 7 days; Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Oral, 10 days; Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Oral, 7 days; Drug: Famotidine (FAM); Tablet, oral, 20 mg, twice daily, 7 days; Drug: Famotidine (FAM); Tablet, oral, 40 mg, twice daily, 7 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir	Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir	Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir	Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest	An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.	Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.
Number of Participants With Abnormalities in Vital Signs	Vital signs include temperature, respiratory rate, seated blood pressure, and heart rate.	Days 1, 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings	ECG findings include heart rate, ECG intervals (including PR, QRS, QT, and corrections to QT using both Bazett's and Fridericia's formulae), and Investigator-identified ECG abnormalities.	Days 1 and 25 (end of study) and at study discharge for those who discontinued prematurely.
Number of Participants With Abnormalities in Laboratory Test Results	PreRX=pretreatment; ULN=upper limit of normal. Neutrophils, (absolute), low (10*3 c/uL): <0.85*PreRx, if PreRx <1.5; <1.5 if PreRx ≥1.5. Alanine aminotransferase, high (U/L): >1.25*PreRx if PreRx >ULN; >1.25*ULN if PreRx ≤ULN. Bilirubin, direct (mg/dL), high: >1.1*ULN if PreRx ≤ULN;> 1.1*ULN if PreRx is missing; >1.25*PreRx if PreRx >ULN. Bilirubin, total (mg/dL), high: >1.1*ULN if PreRx ≤ULN;> 1.1*ULN if PreRx is missing; >1.25*PreRx if PreRx >ULN.	Days 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.

Collaborators and Investigators

• Sponsor: Bristol-Myers Squibb

Study record dates

Study Major Dates

• Study Start: February 1, 2011
• Primary Completion (Actual): June 1, 2011
• Study Completion (Actual): June 1, 2011

Study Registration Dates

• First Submitted: October 29, 2010
• First Submitted That Met QC Criteria: November 1, 2010
• First Posted (Estimate): November 2, 2010

Study Record Updates

• Last Update Posted (Estimate): August 31, 2012
• Last Update Submitted That Met QC Criteria: August 27, 2012
• Last Verified: August 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Gastrointestinal Agents; Protease Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Anti-Ulcer Agents; HIV Protease Inhibitors; Viral Protease Inhibitors; Histamine Antagonists; Histamine Agents; Histamine H2 Antagonists; Tenofovir; Ritonavir; Reverse Transcriptase Inhibitors; Famotidine; Atazanavir Sulfate
• Other Study ID Numbers: AI424-398; 2009-016981-95 (EudraCT Number)